撰文丨王聪 编辑丨王多鱼 排版丨水成文 众所周知，成熟的 红细胞 （RBC） 是人体内唯一没有细胞核的血细胞，然而，红细胞在成熟过程中会留下一些独特的 DNA "记忆碎片"，这些碎片包含了细胞分 裂时错误产生的染色体片段 （微核） 、线粒体 DNA 残留，以及应激损伤导致的特殊断裂位点。 近日， Cell Research 期刊发表了一项突破性研究—— 系统性分析 红细胞内残留 DNA （rbcDNA） ，首次建立了多癌种 rbcDNA 检测模型，只需 1-2 毫升血 液，即可准确识别多种早期癌症，这项研究开创了无创癌症液体活检新范式，让"滴血验癌"迈出关键一步。 该研究以： DNA remnants in red blood cells enable early detection of cancer 为题，于 2025 年 5 月 9 日发表在了 Cell Research 期刊， 西湖大学 高晓飞 研究员为论文通讯作者 ，高晓飞实验室 博士生 孙浩博 、 姚星云 为论文共同第一作者。 癌症 是全球第二大死亡原因 （仅次于心血管疾病） ，其发病率和死亡率呈上升趋势。癌症的早期发现能显著提高患者的生存率，然 ...

Jaguar Health (JAGX) Q1 2025 Earnings Call May 15, 2025 04:15 PM ET Company Participants Lisa Conte - Founder, CEO, President & DirectorCarol Lizak - Chief Financial Officer Operator Greetings, and welcome to Jaguar Health's May fifteen, twenty twenty five Investor Webcast. Before I turn the call over to management, I'd like to remind you that management may look forward looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of pr ...

American Shared Hospital Services (AMS) Q1 2025 Earnings Call May 15, 2025 12:00 PM ET Company Participants Kirin Smith - PresidentRaymond Stachowiak - Executive ChairmanGary Delanois - CEOScott Frech - CFO Conference Call Participants M. Marin - Senior Analyst Operator Good day, and welcome to the American Shared Hospital Services First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Note this event is being recorded. I would now like to turn the conferenc ...

Financial Data and Key Metrics Changes - For Q1 2025, total revenue increased by 17% to $6.1 million compared to $5.2 million in Q1 2024 [16] - Adjusted EBITDA for Q1 2025 was $949,000, down from $1.75 million in Q1 2024 due to lower procedure volume [7][20] - Net loss for Q1 2025 was $625,000 or $0.10 per diluted share, compared to net income of $119,000 or $0.02 per diluted share in Q1 2024 [20] Business Line Data and Key Metrics Changes - Revenue from the Direct Patient Services segment was $3.1 million for Q1 2025, a 224% increase from $963,000 in Q1 2024, driven by the Rhode Island acquisition and operations in Puebla, Mexico [16][17] - Revenue from the equipment leasing segment decreased to $3 million from $4.3 million in Q1 2024 [17] - Gamma Knife revenue declined by 18% to $2.1 million, with a 24% decrease in procedures [18] - Proton Beam Radiation Therapy revenue decreased by 38% to $1.6 million, with a 35% decrease in treatment fractions [18] Market Data and Key Metrics Changes - The company has established Gamma Knife centers in Peru and Ecuador, with a new center in Puebla, Mexico, enhancing its international presence [12] - The Rhode Island acquisition represents a significant expansion in the U.S. market, with plans for a fourth radiation therapy center and the first proton beam facility in the state [13][14] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model, aiming for long-term profitable growth [6][8] - The acquisition of Rhode Island centers and international expansion are key components of the growth strategy [10][12] - Upcoming projects include a new center in Rhode Island and a joint venture for a Gamma Knife center in Guadalajara, Mexico, which is expected to generate revenue by the end of the year [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential despite short-term fluctuations in treatment volumes [15][28] - The company is optimistic about the impact of staffing strategies and upgraded technology on future treatment volumes and profitability [11][15] - Management does not foresee significant risks from potential changes in Medicaid reimbursement rates, as most revenue comes from private insurers and Medicare [23][24] Other Important Information - The company maintains a strong balance sheet with cash and cash equivalents of $11.5 million as of March 31, 2025 [20] - Shareholders' equity was $24.7 million, reflecting a slight decrease from the previous quarter [20] Q&A Session Summary Question: Impact of lower procedure numbers and potential regulatory changes - Management indicated that changes in Medicaid reimbursement are not expected to significantly impact the company, as most revenue is derived from private insurers and Medicare [23][24] Question: Flexibility in managing fixed costs with new center openings - Management confirmed that expanding the Direct Patient Services segment will provide more control over activities and patient growth, enhancing fixed cost absorption [25]

Group 1 - The core finding of the research is the identification of unique genetic characteristics of T cell clones that may predict the efficacy of cancer immunotherapy, paving the way for personalized treatment approaches [1][2] - Immunotherapy is recognized as a revolutionary breakthrough in cancer treatment, capable of precisely eliminating cancer cells by activating the immune system, but individual patient differences pose significant challenges to its widespread application [1] - The research involved a meta-analysis of single-cell RNA sequencing and T cell receptor sequencing data from numerous cancer patients who underwent immunotherapy, focusing on the relationship between T cell clone characteristics and the success of the therapy [1] Group 2 - The study revealed that while T cell clones exist in both responsive and non-responsive cancer patients, those in responsive patients exhibit a distinct genetic feature and enhanced immune activity due to immunotherapy [2] - It was determined that activating T cell clones present only within tumors, rather than those found in both tumors and blood, is crucial for improving the effectiveness of immunotherapy in treating cancer [2] - This research provides significant insights into the dynamic mechanisms of the human immune system in the cancer fighting process, as published in the latest issue of the journal "Cell Genomics" [2]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 CAR-T 细胞疗法 是癌症治疗领域的革命性突破，在白血病等血液类肿瘤中显示出了强大的治疗效果，近 年来还成功治疗了系统性红斑狼疮等多种自身免疫疾病。 然而， CAR-T 细胞疗法 却在临床应用中埋藏着一个意想不到的隐患—— 接受 CAR-T 细胞 治疗的部分患 者出现了记忆力减退、注意力不集中等"脑雾"症状。 2025 年 5 月 12 日，斯坦福大学医学院的研究人员在国际顶尖学术期刊 Cell 上发表了题为： Immunotherapy-related cognitive impairment after CAR T cell therapy in mice 的研究论文。 在此基础上， 短暂耗竭小胶质细胞 或 阻断 CCR3 ，可挽救 CAR-T 细胞治疗后小鼠的少突胶质细胞缺 陷，并在注意力和短期记忆功能的行为测试中恢复其认知表现。 癌症治疗相关认知障碍 （ Cancer therapy-related cognitive impairment，CRCI） 影响着众多癌症幸存 者。化疗等传统癌症疗法常常与一种持续性认知障碍综合征相关联，其特征表现为记忆、注意力、信 ...

Lucid Diagnostics (LUCD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Matt Riley - Director of Investor RelationsLishan Aklog - Chairman & CEODennis McGrath - CFO Conference Call Participants Mark Massaro - MD & Senior Equity Research AnalystKyle Mikson - Managing Director & Senior Research AnalystMike Matson - Senior Equity Research AnalystJeremy Pearlman - Equity AnalystRoss Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsEdward Woo - Director of Research & Senior ...

在此基础上，研究团队成功设计并合成了一类可激活铁死亡的小分子，即"磷脂降解剂"。该分子一端可 靶向细胞膜并进入细胞的消化器官溶酶体，另一端能增强癌细胞溶酶体中富集铁的反应性，从而触发铁 死亡。 研究人员将这类分子中的一种设计为具备荧光特性，可通过荧光显微镜追踪其在细胞中的定位，并确认 其确实聚集在溶酶体中。在给实验动物注射这种分子后，研究人员在转移性乳腺癌的临床前模型中观察 到肿瘤生长明显减缓；此外，在患者的胰腺癌及肉瘤活检样本中，也发现了显著的细胞毒性反应。这些 结果确认了该治疗方案在临床前阶段对常规化疗疗效有限的癌种具有显著效果。 相关研究论文已于日前发表在英国《自然》杂志上。接下来，研究人员还需要进行临床研究来验证这一 治疗方案能否成为当前常规化疗之外的补充疗法，特别靶向那些具有转移潜能且对标准治疗耐药的癌细 胞。（完） 据悉，当前的抗癌治疗主要针对快速增殖的原发肿瘤细胞，但对于那些具有转移潜能、能够适应现有治 疗的癌细胞，却难以有效清除，而癌症患者中有70%的死亡正是由病灶转移引起。 来自法国居里研究所、国家科学研究中心等机构的研究人员，聚焦一种具有高度转移潜能的"持久性癌 细胞"。这类细胞表面高表达 ...

Relmada Therapeutics (RLMD) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Brian Ritchie - Managing DirectorSergio Traversa - CEO & Member of Board of DirectorsMaged Shenouda - Chief Financial OfficerUy Ear - Vice PresidentYair Lotan - Professor of Urology & Chief of Urologic OncologyMatthew Barcus - Senior Research Associate Operator Good afternoon. Welcome to Ramada Therapeutics First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A ...

UroGen Pharma (URGN) Q1 2025 Earnings Call May 12, 2025 10:00 AM ET Company Participants Vincent Perrone - Senior Director of Investor RelationsLiz Barrett - President & CEOMark Schoenberg - Chief Medical OfficerDavid Lin - Chief Commercial OfficerChris Degnan - CFOKelsey Goodwin - Vice PresidentGeorge Farmer - Managing Director Conference Call Participants Tara Bancroft - Director, Senior Analyst, Biotech Equity ResearchLeland Gershell - MD & Senior Biotechnology AnalystRaghuram Selvaraju - Managing Direct ...